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OBJECTIVE — The purpose of this study was to investigate whether genetic variants could
inﬂuence the antidiabetic efﬁcacy of gliclazide in type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — A total of 1,268 type 2 diabetic patients
whose diabetes was diagnosed within the past 5 years and who had no recent hypoglycemic
treatment were enrolled from 23 hospitals in China. All of the patients were treated with
gliclazidefor8weeks.Fastingandoralglucosetolerancetest2-hplasmaglucose,fastinginsulin,
and A1C were measured at baseline and after 8 weeks of treatment. We used two independent
cohorts to test the associations of 25 single nuclear polymorphisms in 11 candidate genes with
the antidiabetic efﬁcacy of gliclazide. A general linear regression model was used to test the
association with adjustment for important covariates.
RESULTS — After 8 weeks of gliclazide therapy, mean fasting plasma glucose (FPG) was
reducedfrom11.1mmol/latbaselineto7.7mmol/l.Incohort1,wegenotypedall25SNPs(n
661) and found that Ser1369Ala of the ABCC8 gene and rs5210 of the KCNJ11 gene were
signiﬁcantlyassociatedwithdecreasesinFPG(P0.002).WefurthergenotypedSer1369Alain
cohort 2 (n  607) and conﬁrmed the association identiﬁed in cohort 1. In the pooled analysis,
compared with subjects with the Ser/Ser genotype, subjects with the Ala/Ala genotype had a
7.7%greaterdecreaseinFPG(P0.001),an11.9%greaterdecreasein2-hplasmaglucose(P
0.003),anda3.5%greaterdecreaseinA1C(P0.06)after8weeksoftreatmentwithgliclazide.
CONCLUSIONS — In two independent cohorts of Chinese type 2 diabetic patients, we
found consistent evidence that the Ser1369Ala variant in the ABCC8 gene can inﬂuence the
antidiabetic efﬁcacy of gliclazide.
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T
heepidemicoftype2diabetesinthe
last decade in both developed and
developing countries has made it a
major threat to global public health. At
least 171 million people worldwide had
diabetes in 2000, and this ﬁgure is likely
tomorethandoubleby2030toreach366
million (1). The majority of diabetes is
type 2 diabetes. Most of the recent rise in
diabetes prevalence is probably a result of
lifestyle and dietary changes, but there is
also clear evidence for genetic predisposi-
tion to this complex disease. During the
last decade, molecular genetic studies of
type 2 diabetes have shown signiﬁcant
progress (2). Five genome-wide associa-
tion studies have been published since
February 2007, increasing the number of
conﬁrmed type 2 diabetes susceptibility
loci from three (PPARG, KCNJ11, and
TCF7L2) to 9 (with the addition of
CDKAL1, CDKN2A/B, IGF2BP2, HHEX/
IDE, FTO, and SLC30A8) (2). In addition,
studies have lent support for the involve-
mentofmanyothergenes,suchasABCC8
(3–6).Incontrast,fewstudieshaveinves-
tigated whether genetic variants may
modulate the response to antidiabetic
agents in type 2 diabetic patients (7–9).
Such information can assist clinicians in
developing individualized treatment
plans that will maximize therapeutic efﬁ-
cacy and minimize side effects.
Sulfonylurea is a widely used oral hy-
poglycemic agent. Most type 2 diabetic
patients respond well to this agent, but
variable efﬁcacy is seen, and primary fail-
ure to sulfonylurea treatment is seen in a
small portion of patients. Secondary fail-
ure of sulfonylurea monotherapy devel-
ops in 34% of patients at 5 years (10).
To explore the underlying genetic factors
that may explain individual variable re-
sponse to sulfonylurea, we conducted a
hospital-based pharmacogenetic study.
Our goal was to examine whether type 2
diabetes candidate gene variants can in-
ﬂuence the antidiabetic efﬁcacy of glicla-
zide, a commonly used sulfonylurea
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abetic patients.
RESEARCH DESIGN AND
METHODS— We conducted a hospi-
tal-based pharmacogenetic study of gli-
clazide in type 2 diabetic patients in
China between December 2003 and Au-
gust 2005. Patients were recruited from
23 hospitals located in Harbin of the Hei-
longjiang province, Beijing, Tianjin, and
Hefei and Anqing of the Anhui province
following the same study protocol. The
23 hospitals selected were the major hos-
pitals in the study regions. These hospi-
tals were all government owned but were
run independently.
Type 2 diabetes was diagnosed ac-
cordingtoAmericanDiabetesAssociation
criteria (11). To reduce the clinical heter-
ogeneityoftype2diabetes,thisstudywas
limited to Han Chinese subjects with on-
set of type 2 diabetes after the age of 35
years who also met all of the following
criteria: 1) diabetes diagnosed within the
past5yearsandnoantidiabetestreatment
within the past 2 months, 2)B M I28
kg/m
2, and 3) fasting plasma glucose
(FPG) between 7.8 and 15.0 mmol/l. We
excluded patients with any acute or
chronic diabetes complications, unstable
angina, myocardial infarction or heart
failure, chronic gastrointestinal disease or
abnormal liver function, renal insufﬁ-
ciency, or clinical problems potentially
causing hyperglycemia, including infec-
tion, thyroid disease, or surgery. We also
excluded those taking other medications,
such as corticosteroids or estrogen, as
well as cancer patients and pregnant or
breast-feeding women.
Subjects were enrolled from the out-
patient clinics of the participating hospi-
tals. After giving written informed
consent, patients started an 8-week treat-
ment with gliclazide (Tianjin Huajin
Pharmaceutical Company, Tianjin,
China). The initial dose of gliclazide was
40mgtwicedaily.Thepatientscontinued
their initial dosage throughout the 8
weeks of treatment or had their dose in-
creased to 80 mg twice daily if FPG was
7.0 mmol/l after 2 weeks and increased
again by 40 mg (from 80 to 120 mg or
from 40 to 80 mg) twice daily if FPG was
7.0 mmol/l after 4 weeks of treatment.
The study was approved by the institu-
tional review boards of Anhui Medical
University and all participating hospitals.
Data collection and clinical
laboratory methods
At the ﬁrst visit (screening), a standard
questionnaire was administered to collect
information on medical history and med-
ication, diet, exercise, and lifestyle factors
including smoking and alcohol drinking,
householdincome,educationallevel,and
occupation. Height, weight, waist cir-
cumference, and blood pressure were
measured using a standard protocol.
Overnight (10 h) fasting blood samples
were collected to determine FPG, insulin,
A1C, lipid proﬁle, liver and renal func-
tion, and routine blood cell counts. All
study patients underwent a 75-g oral glu-
cose tolerance test (OGTT) unless FPG
was 13.0 mmol/l, and blood samples
were collected after2ht odetermine
plasma glucose. Diabetes education was
also provided to all potentially eligible
subjects during the screening visit. The
education included a brief introduction
on type 2 diabetes, with a particular focus
ondietandphysicalexercise.Inaddition,
a handbook with more detailed informa-
tion was given to the subjects for them to
read.
All study patients returned for fol-
low-up every 2 weeks. A follow-up ques-
tionnaire was administered to monitor
patients’ medications, diet, exercise, and
side effects of gliclazide. Speciﬁcally, the
research staff documented whether the
subjects complied with the treatment and
followed the instruction for diet (with a
grade of very good, fair, and poor) and
exercisetime.Thesideeffectsofgliclazide
that we monitored in our study included
hypoglycemia, abnormal liver function,
skin rash, or any other symptoms re-
ported by patients.
FPG (at the 29th day) or fasting ﬁn-
gerstick glucose (at the 13th and 43rd
days) were measured for each subject. At




Plasma glucose, serum lipids, and
liver and renal function were measured at
the local hospitals using an automatic an-
alyzer (Hitachi 7020; Hitachi, Tokyo, Ja-
pan, or a similar model). The A1C values
were determined with a high-perfor-
mance liquid chromatography method at
four major participating hospitals using
the unique standard procedure and the
same reagents. Serum insulin was mea-
suredusinganelectrochemiluminescence
method on an Elecsys 2010 system
(RocheDiagnostics,Basel,Switzerland)at
our central laboratory. The insulin secre-
tion (HOMA-B) and resistance index of
homeostatic model assessment (HOMA-
IR) were calculated according to fasting
glucose and insulin level using the
HOMA2 calculator (http://www.dtu.ox.
ac.uk/homa).
Candidate gene and SNP selection
and genotyping method
We selected 11 type 2 diabetes candidate
genes on the basis of the published liter-
ature (see Table 2). For each gene, one to
sixnonsynonymousorhaplotype-tagging
SNPs, according to the HapMap data
(http://www.hapmap.org/), were se-
lected.Inourcentrallaboratory,wegeno-
typed all 25 selected SNPs for all of the
subjects in cohort 1, which consisted of
661 patients from 12 participating hospi-
talslocatedinnorthernChina.Wefurther
genotyped one signiﬁcant nonsynony-
mous SNP (rs757110) identiﬁed in co-
hort 1 for all subjects in cohort 2, which
consisted of 607 patients from the re-
maining 11 participating hospitals lo-
cated in southern China. The reasons for
the two-phase genotyping were twofold:
reduce the genotyping cost and minimize
the multiple testing problem, which
could inﬂate type I error.
DNA was extracted from leukocytes
in peripheral blood using standard tech-
niques. Genotyping was performed by
TaqMan genotyping assays that were de-
signedandmanufacturedbyAppliedBio-
systems (Foster City, CA).
Statistical analysis. All data analyses
were performed using SAS (version 8;
SAS Institute, Cary, NC). The phenotype
data are shown as mean  SD and the
differences between groups were tested
using t tests or one-way ANOVA. The as-
sociations between quantitative pheno-
types (FPG, 2-h plasma glucose, or A1C
decrease [percent]) and genotypes were
testedusinglinearregressionmodels.The
associations between binary phenotypes
(response/nonresponse) and genotypes
were tested using a logistic repression
model. All analyses were performed with
or without adjustment for age, sex, BMI,
total gliclazide dosage, and baseline
HOMA-B and HOMA-IR. All P values
were two tailed.
RESULTS— We enrolled a total of
1,464 patients; 196 patients were lost to
follow-up during the course of treatment.
The major reason for those lost to fol-
low-up was inconvenience because they
livedtoofarfromthestudyhospitals.The
Ser1369Ala variant in ABCC8 and gliclazide
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those who were lost to follow-up were
similar (P  0.05) in major baseline de-
mographicandclinicalcharacteristics,in-
cluding age (50.1  8.4 vs. 49.2  9.4
years), sex (men 54 vs. 49%), age of diag-
nosis of type 2 diabetes (49.4  8.4 vs.
48.5  10.4 years), fasting glucose
(11.1  2.9 vs. 11.4  3.2 mmol/l), in-
sulin (5.6  2.2 vs. 5.3  2.5 IU/ml),
A1C (8.4  1.9 vs. 8.1  2.1%), and
blood pressure (126.1  17.3/81.3 
10.8 vs. 125.6  17.4/80.5  10.2
mmHg). Some difference was noted for
total cholesterol (5.2  1.4 vs. 5.6  4.2
mmol/l, P  0.01) and triglycerides
(2.1  1.7 vs. 2.8  4.1 mmol/l, P 
0.01).
We analyzed the data of 1,268 pa-
tients who completed the entire study
procedures. Most patients followed the
instructions for diet and exercise well.
The percentage of patients with poor diet
control was consistently 6% through-
out the whole trial, 42 and 53% of pa-
tients had fair or good diet control,
respectively, at day 57. The mean weekly
exercise time was 8 h. In 245 and 111
patients, respectively, the dose of glicla-
zide was increased at days 15 and 29 ac-
cording to the study protocol to achieve
better glycemic control. The demo-
graphic and clinical characteristics of the
studypatientsaresummarizedinTable1.
The mean age of the patients was 50.4
years and 54.4% of the patients were
male. After 8 weeks of gliclazide therapy,
the patients’ mean FPG decreased from
11.1 mmol/l at baseline to 7.7 mmol/l
(mean  SD decrease 3.4  2.8 mmol/l),
and 43.7 and 63.0% patients lowered
their FPG to 7.0 and 7.8 mmol/l, re-
spectively.A1Cdecreasedfrom8.11.9
to6.91.3%(1.41.6%).Meanfasting
insulin level and HOMA-B increased by
22 and 122%, respectively, but the mean
HOMA-IR did not change signiﬁcantly
(Table 1). The patients included in the
cohort 1 and 2 studies were similar with
regard to age and sex distribution. How-
ever, patients in cohort 2 had lower BMI
and a lower level of A1C, fasting insulin,
HOMA-B, and HOMA-IR than those in
cohort 1 (Table 1). This may reﬂect pop-
ulation differences across geographic dif-
ferences between cohort 1 patients, who
were mainly from northern China, and
cohort 2 patients, who were from south-
ern China.
We ﬁrst explored the possible inﬂu-
ence of demographic and clinical vari-
ables, including age, sex, BMI, total
dosage of gliclazide during the 8 weeks of
treatment, and baseline HOMA-B and
HOMA-IR, on percent decrease in FPG
after 8 weeks of gliclazide therapy. We
found that the last three factors were sig-
niﬁcantly associated with the antidiabetic
efﬁcacy of gliclazide (P  0.001). Thus,
thesefactors,alongwithageandsex,were
adjusted in the subsequent genetic asso-
ciation analyses. The distribution of pa-
tients with different levels of diet control
(good, fair, or poor) and average exercise
hours among three genotype groups of
Ser1369Ala polymorphism were not sig-
niﬁcantly different (data not shown).
The minor allele frequencies of the
SNPs we genotyped in the cohort 1 study
ranged from 1 to 50% (Table 2). Geno-
typesofallSNPswereinHardy-Weinberg
equilibrium. We found that 2 of the 25
SNPs, rs757110 and rs5210, were signif-
icantly associated with percent decrease
of FPG, even after Bonferroni correction
formultipletesting(P0.002)(Table2).
SNP rs757110, which is located in exon
33 of the ABCC8 gene (encoding the sul-
fonylurea receptor), results in an amino
acid substitution of Ser/Ala. SNP rs5210,
which is located in the 3 untranslated
region of KCNJ11, is located in the same
chromosome as rs757110 and is only 10
kb apart. However, the two SNPs are not
in signiﬁcant linkage disequilibrium (LD)
(D0.08, R
2  0.006).
We genotyped rs757110 for all of the
study patients in the cohort 2 study and
conﬁrmed the signiﬁcant association
identiﬁedincohort1(P0.002,additive
model). In the pooled analysis (combin-
ing cohort 1 and cohort 2 patients), we
found that patients with Ser/Ala and Ala/
Ala genotypes had 2.8% (P  0.076) and
7.7% (P  0.001) greater decreases in
FPG, and 10.8% (P  0.001) and 11.9%
(P  0.003) greater decreases in OGTT
2-h plasma glucose, respectively, com-
pared with those with the Ser/Ser geno-
type (Table 3). The decrease in A1C after
8 weeks of treatment with gliclazide was
3.5% greater in patients with the Ala/Ala
Table 1—Characteristics of patients in cohort 1 and cohort 2
Characteristics Cohort 1 Cohort 2 Pooled
n 661 607 1,268
Age (years) 50.2  8.0 50.5  8.6 50.4  8.3
Men (%) 54.8 54.0 54.4
Age at diagnosis (years)* 49.0  7.8 49.1  8.5 49.1  8.1
Duration of diabetes (months)* 14.2  19.9 14.6  22.3 14.4  20.9
BMI (kg/m
2) 24.9  2.9 24.3  3.4† 24.9  8.4
Waist circumference (cm) 88.7  9.0 86.7  9.5† 87.8  9.3
Baseline
FPG(mmol/l) 10.8  2.6 11.4  3.2† 11.1  2.9
2-h plasma glucose (mmol/l)‡ 18.9  4.4 18.3  5.0† 18.6  4.7
A1C (%)§ 8.5  1.8 8.3  2.1 8.1  1.9
Fasting insulin (IU/ml)¶ 6.7  2.0 5.0  2.2† 5.5  2.2
HOMA-B¶ 20.1  2.0 14.9  2.5† 18.2  2.2
HOMA-IR¶ 1.0  2.0 0.8  2.0† 0.9  2.0
Total cholesterol (mmol/l) 5.1  1.1 5.2  1.6 5.2  1.4
HDL cholesterol (mmol/l) 1.3  0.4 1.5  3.2 1.4  2.2
Triglyceride (mmol/l) 2.2  1.6 2.0  1.9 2.1  1.7
FPG at day 29 (mmol/l) 7.9  2.1 8.1  2.4 8.0  2.3
At day 57
FPG(mmol/l) 7.7  2.1 7.7  2.4 7.7  2.3**
2-h plasma glucose (mmol/l)†† 14.6  4.4 13.9  5.1† 14.3  4.7**
A1C (%)‡‡ 7.1  1.3 6.6  1.4† 6.9  1.3**
Fasting insulin (IU/ml)§§ 7.4  2.0 5.5  2.5† 6.7  2.2**
HOMA-B§§ 44.7  1.8 33.1  2.5† 40.4  2.2**
HOMA-IR§§ 1.1  2.0 0.8  2.0† 1.0  2.0
Data are means  SD. *The sample sizes of cohort 1, cohort 2, and total are 383, 291, and 674, respectively.
†P0.05comparedwithcohort1.‡Thesamplesizesofcohort1,cohort2,andtotalare534,429,and963,
respectively. §The sample sizes of cohort 1, cohort 2, and total are 378, 321, and 699, respectively. Log
transformed before the analysis; geometric mean and anti-log SD are presented. ¶The sample sizes of cohort
1,cohort2,andtotalare572,465,and1,037,respectively.**P0.05comparedwithbaseline,ttest.††The
sample sizes of cohort 1, cohort 2, and total are 646, 520, and 1,166, respectively. ‡‡The sample sizes of
cohort 1, cohort 2, and total are 460, 249, and 709, respectively. §§The sample sizes of cohort 1, cohort 2,
and total are 598, 304, and 902, respectively.
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genotype (P  0.06) (Table 3). The mean
gliclazide dosage requirements for Ser/
Ser, Ser/Ala, and Ala/Ala genotypes were
83.7, 77.6, and 78.4 mg/day, respec-
tively. When we deﬁne FPG at day 57 as
7.8mmol/l in response to gliclazide
therapy, the patients with the Ser/Ala and
Ala/Ala genotypes had odds ratios of 1.4
(95% CI 1.0–2.1, P  0.06) and 2.2
(1.4–3.6,P0.001),respectively,forre-
sponse to gliclazide therapy compared
with subjects with Ser/Ser genotype.
We did not ﬁnd any signiﬁcant asso-
ciationbetweentheSer1369Alapolymor-
phismandfastinginsulinlevel,HOMA-B,
and HOMA-IR, either at baseline or af-
ter treatment, or the change in fasting
insulin level or HOMA-B after gliclazide
treatment. Interestingly, however,
mean HOMA-IR decreased signiﬁcantly
Table 3—Association of Ser1369Ala genotype with percentage decrease in FPG, 2-h plasma glucose, and A1C after 8 weeks of gliclazide
treatment in type 2 diabetic patients (pooled sample of cohort 1 and cohort 2)
Outcome phenotype Genotype n Baseline Day 57 Decrease (%)
Regression,
 (Se)* P
FPG (mmol/l) Ser/Ser 363 11.1  2.9 7.9  2.4 26.1  20.2 — —
Ser/Ala 562 11.0  2.9 7.6  2.0 27.9  18.9 2.8 (1.6) 0.076
Ala/Ala 224 11.5  3.3 7.6  2.5 31.6  19.8 7.7 (1.9) 0.001
2-h plasma glucose (mmol/l) Ser/Ser 269 18.9  4.7 15.2  5.9 22.3  22.8 — —
Ser/Ala 404 18.4  4.7 14.0  4.1 23.3  23.4 10.8 (3.3) 0.001
Ala/Ala 157 18.8  4.4 13.9  4.4 27.6  20.3 11.9 (4.1) 0.003
A1C (%) Ser/Ser 151 8.4  1.9 7.0  1.5 14.2  17.6 — —
Ser/Ala 251 8.3  2.0 6.8  1.2 15.8  15.3 1.9 (1.4) 0.195
Ala/Ala 106 8.7  2.0 7.0  1.4 17.4  13.5 3.5 (1.8) 0.060
Data are means  SD unless otherwise indicated. *Multiple line regression model, outcome variables were percent decrease in FPG, 2-h plasma glucose, and A1C,
respectively. The analysis adjusted for age, gender, total gliclazide dose, and baseline HOMA-B and HOMA-IR.  (Se), regression coefﬁcient (SE) for genotype using
Ser/Ser as reference.
Table 2—Associations of 25 candidate SNPs with percentage decrease in FPG after 8-week gliclazide treatment in type 2 diabetic patients of
cohort 1









ABCC8 Sulfonylurea receptor (SUR1) rs757110 1,369 Ser3Ala 0.432 0.002
rs1799854 — — 0.416 0.498
rs2074312 — — 0.500 0.031
rs2237984 — — 0.369 0.616
rs2237981 — — 0.256 0.046
Kir6.2 (KCNJ11) ATP-sensitive potassium channel,
Kir6.2
rs5210 — — 0.480 0.002
ENSA Endosulﬁne alpha rs7517 — — 0.222 0.085
PPARG Peroxisome proliferative activated
receptor 	
rs2972164 — — 0.084 0.284
rs10510412 — — 0.346 0.480
rs2959273 — — 0.412 0.332
CAPN10 Calpain 10 rs10933620 — — 0.342 0.462
rs3792267 — — 0.107 0.765
rs2975760 — — 0.106 0.958
TCF1 Hepatocyte nuclear factor 1
 rs2464195 — — 0.498 0.490
rs1169300 — — 0.499 0.457
IRS1 Insulin receptor substrate 1 rs1801278 972 Gly3Arg 0.009 0.905
rs9653366 — — 0.189 0.065
rs10498210 — — 0.073 0.336
rs12052364 — — 0.172 0.039
GLP1R Glucagon-like peptide 1 receptor rs1042044 260 Phe3Leu 0.492 0.496
UCP2 Uncoupling protein 2 rs660339 55 Val3Ala 0.467 0.739
PPARGC1A Peroxisome proliferative activated
receptor 	, coactivator 1

rs8192678 482 Ser3Gly 0.425 0.596
rs3736265 612 Thr3Met 0.175 0.780
ADRB2 2-Adrenergic receptor rs1042713 16 Arg3Gly 0.422 0.386
rs1042714 27 Gln3Glu 0.099 0.897
*Linear regression under additive model with adjustment for age, sex, total gliclazide dose, baseline HOMA-B, and HOMA-IR.
Ser1369Ala variant in ABCC8 and gliclazide
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theAla/Alagenotype,butnotinpatients
with the Ser/Ser or Ser/Ala genotypes
(data not shown).
Of the 1,268 study subjects, 273
(21.5%) met the criteria for metabolic
syndrome. However, we did not ﬁnd any
associationbetweentheSer1396Alapoly-
morphism and BMI or metabolic syn-
drome, and further adjustment for
metabolic syndrome in the analysis did
not alter the association between the
Ser1396Ala polymorphism and antidia-
betic efﬁcacy (data not shown).
CONCLUSIONS — The sulfonylurea
receptor (SUR1), encoded by the ABCC8
gene, is the internal molecular target for
gliclazide. Genetic variants of ABCC8,
such as exon 16 3t/c, exon 18 T759T,
and most recently the missense mutation
Y356C, have been reported to be associ-
ated with type 2 diabetes (3,5,12,13).
Some missense mutations other than
Ser1369Ala in the ABCC8 gene have been
identiﬁed as causing neonatal diabetes
(14). To our knowledge, this study is the
ﬁrst to report the association between a
genetic variant of the ABCC8 gene and
therapeutic efﬁcacy of sulfonylurea in
type 2 diabetic patients.
The major strengths of this study in-
clude large sample size, multiple well-
measured phenotypes, and a prospective
design. However, cautions are needed in
interpreting our ﬁndings. First, we only
studied the response to gliclazide for a
short period, i.e., the initial response to
monotherapywithasulfonylurea.Theas-
sociation of Ser1369Ala with the long-
term response to gliclazide remains
unknown. Second, we excluded obese
patients. The InterASIA study, a recent
large-scale nationwide epidemiological
study in China, showed that 18.7% of di-
abetic subjects were obese (BMI 28 kg/
m
2) (15). Thus, our study sample should
represent 80% of type 2 diabetic pa-
tients in China.
Population admixture, which may
lead to false-positive association, is a ma-
jor concern in a genetic association study.
Given the obvious difference between the
northern and southern Han Chinese, we
analyzed the two cohorts separately to
minimize potential confounding due to
population admixture. The differential
baseline characteristics of the two study
cohorts may affect antidiabetic efﬁcacy of
the treatment; however, it would not be
likely to inﬂuence the main purpose of
this pharmacogenetic study. The fact that
consistent associations were observed in




a common variant of the KCNJ11 gene in
cohort 2. It is possible that Ser1396Ala
SNP is not a causal variant. Instead, the
association between Ser1396Ala and an-
tidiabetic efﬁcacy may be a result of other
functional mutations that are in high LD
with Ser1396Ala. Future studies should
screen for mutations within both the
SUR1 gene and nearby genes, such as
KCNJ11.
The association between A1C and the
Ser1369Alapolymorphismwasonlymar-
ginally signiﬁcant. We speculate that sig-
niﬁcance would have been achieved if
we had extended the trial for another 4
weeks, because hemoglobin turns over
every 3 months. Another reason was that
missing data for A1C may have affected
ourstatisticalpowertodetectasigniﬁcant
association.
Finally, we excluded patients with
longstanding diabetes (5 years), who
were more likely to have decreased -cell
function and to have complications of the
disease (which may affect the therapeutic
response to gliclazide). Caution is needed
in generalizing our ﬁndings to patients
with longstanding diabetes.
Although our study may not have an
immediate impact on clinical practice, it
may stimulate more investigations in this
area. Pharmacogenetics is an emerging
discipline investigating the inﬂuence of
genetic variants on drug response. It is an
important path toward personalized
medicine. So far, only a few pharmacoge-
netic studies on diabetes have been re-
ported. Patients with maturity-onset
diabetes of the young who had the hepa-
tocyte nuclear factor-1
 mutation were
reported to be extremely sensitive to the
hypoglycemic effects of sulfonylureas
(16). Recently, Shu et al. (9) took a mul-
tipronged approach, using cell-based ex-
periments, in vivo studies in mice, and in
vitro human trials (healthy volunteers),
and demonstrated that genetic variances
of organic cation transporter 1 (OCT1)
had a signiﬁcant impact on response to
metformin, a common antidiabetic agent
for type 2 diabetes. However, a small
study (n  24 responders and 9 nonre-
sponders)didnotconﬁrmtheassociation
of OCT1 gene polymorphisms and re-
sponse to metformin in diabetic patients
(8). Sesti et al. (17) reported that the
E23K variants in KCNJ11 are associated
with increased risk for secondary failure
of sulfonylurea treatment in type 2 dia-
betic patients. The E23K polymorphism
isinhighLD(D0.98,R
20.87)with
the Ser1369Ala of the ABCC8 gene (5), so
we did not include the E23K polymor-
phisminourstudy.However,wedidﬁnd
that a common variant of KCNJ11,
rs5210, was associated with gliclazide re-
sponse in our cohort 1 study.
SUR1 is an important subunit of the
ATP-sensitive K
 channel, which is a key
component in regulation of insulin secre-
tion from pancreatic -cell membranes.
The Ser1369Ala variant is located in the
second nucleotide-binding fold, a func-
tionally important region of the ABCC8
gene. It has not been found to be asso-
ciated with type 2 diabetes in either
Caucasians (13) or Japanese (5,18). In-
terestingly, the ABCC8 Ser1369Ala
polymorphism was recently reported to
inﬂuence progression to diabetes (6). Al-
though the Ser1369Ala is a missense
polymorphism, its inﬂuence on SUR1
function still remains uncertain. Florez et
al. (6) found the Ala/Ala carriers had a
signiﬁcantly lower insulin index, i.e., in-
sulin secretion function, compared with
Ser/Ser carriers in subjects with impaired
glucosetolerance.However,otherstudies
did not ﬁnd any association between the
Ser1369Ala variant and insulin secretion
in nondiabetic subjects (19,20). We also
did not ﬁnd any association between the
Ser1369Alavariantandfastingplasmain-
sulin level or HOMA-B, an indicator for
insulin secretion, either at baseline or af-
ter gliclazide treatment. The improve-
ment in insulin resistance (HOMA-IR) in
the Ser/Ser genotype group was probably
due to good glucose control after glicla-
zide treatment.
In summary, we found that a com-
mon variant in the ABCC8 gene,
Ser1369Ala, was signiﬁcantly associated
with the antidiabetic efﬁcacy of gliclazide
in nonobese type 2 diabetic patients in
China. Patients with the Ala/Ala genotype
appeared to respond signiﬁcantly better
to gliclazide than did patients with the
Ser/Sergenotype.Althoughthedifference
may have limited impact on clinical prac-
tice, our results did demonstrate that ge-
netic variation can be a signiﬁcant
determinant of response to oral hypogly-
cemic drugs.
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